Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 08-Nov-23 8:31 PM View:  | Gill Simba President & CEO Director | Evelo Biosciences, Inc. (EVLO) | 08-Nov-23 | Planned Option Sale | 172 | $0.33 | $56.76 | (< 1%) 17.93K to 17.76K | |
| 08-Nov-23 8:32 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 08-Nov-23 | Planned Option Sale | 3,103 | $0.33 | $1,023.99 | (15%) 20.09K to 16.98K | |
| 08-Nov-23 8:31 PM View: | Thorell Marella Chief Financial Officer | Evelo Biosciences, Inc. (EVLO) | 08-Nov-23 | Planned Option Sale | 1,811 | $0.33 | $597.63 | (8%) 24.07K to 22.26K | |
| 08-Nov-23 8:32 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 08-Nov-23 | Planned Option Sale | 3,163 | $0.33 | $1,043.79 | (11%) 28.89K to 25.73K | |
| 08-Nov-23 8:32 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 07-Nov-23 | Option Exercise | 6,500 | -- | -- | 48% 13.59K to 20.09K | |
| 08-Nov-23 8:31 PM View: | Thorell Marella Chief Financial Officer | Evelo Biosciences, Inc. (EVLO) | 07-Nov-23 | Option Exercise | 6,500 | -- | -- | 37% 17.57K to 24.07K | |
| 08-Nov-23 8:31 PM View: | Gill Simba President & CEO Director | Evelo Biosciences, Inc. (EVLO) | 07-Nov-23 | Option Exercise | 1,172 | -- | -- | 7% 16.76K to 17.93K | |
| 08-Nov-23 8:32 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 07-Nov-23 | Option Exercise | 6,625 | -- | -- | 30% 22.27K to 28.89K | |
| 03-Nov-23 4:11 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 02-Nov-23 | Planned Option Sale | 6,854 | $0.33 | $2,261.82 | (34%) 20.44K to 13.59K | |
| 03-Nov-23 4:11 PM View: | Thorell Marella Chief Financial Officer | Evelo Biosciences, Inc. (EVLO) | 02-Nov-23 | Planned Option Sale | 3,999 | $0.33 | $1,319.67 | (19%) 21.57K to 17.57K | |
| 03-Nov-23 4:12 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 02-Nov-23 | Planned Option Sale | 6,854 | $0.33 | $2,261.82 | (24%) 29.12K to 22.27K | |
| 03-Nov-23 4:11 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 01-Nov-23 | Option Exercise | 12,500 | -- | -- | 157% 7.94K to 20.44K | |
| 03-Nov-23 4:11 PM View: | Thorell Marella Chief Financial Officer | Evelo Biosciences, Inc. (EVLO) | 01-Nov-23 | Option Exercise | 12,500 | -- | -- | 138% 9.07K to 21.57K | |
| 03-Nov-23 4:12 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 01-Nov-23 | Option Exercise | 12,500 | -- | -- | 75% 16.62K to 29.12K | |
| 29-Sep-23 4:02 PM View: | Gill Simba President & CEO Director | Evelo Biosciences, Inc. (EVLO) | 28-Sep-23 | Planned Option Sale | 1,996 | $3.94 | $7,864.24 | (11%) 18.75K to 16.76K | |
| 29-Sep-23 4:02 PM View: | Gill Simba President & CEO Director | Evelo Biosciences, Inc. (EVLO) | 27-Sep-23 | Option Exercise | 15,000 | -- | -- | 400% 3.75K to 18.75K | |
| 09-Aug-23 8:42 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 08-Aug-23 | Planned Option Sale | 3,434 | $9.51 | $32,657.30 | (30%) 11.38K to 7.94K | |
| 09-Aug-23 8:42 PM View: | Thorell Marella Chief Financial Officer | Evelo Biosciences, Inc. (EVLO) | 08-Aug-23 | Planned Option Sale | 2,004 | $9.51 | $19,058.00 | (18%) 11.07K to 9.07K | |
| 09-Aug-23 8:43 PM View: | Gill Simba President & CEO Director | Evelo Biosciences, Inc. (EVLO) | 08-Aug-23 | Planned Option Sale | 342 | $9.51 | $3,252.42 | (8%) 4.1K to 3.75K | |
| 09-Aug-23 8:44 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 08-Aug-23 | Planned Option Sale | 3,128 | $9.51 | $29,747.30 | (16%) 19.75K to 16.62K | |
| 09-Aug-23 8:43 PM View: | Gill Simba President & CEO Director | Evelo Biosciences, Inc. (EVLO) | 07-Aug-23 | Option Exercise | 1,171 | -- | -- | 40% 2.92K to 4.1K | |
| 09-Aug-23 8:44 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 07-Aug-23 | Option Exercise | 6,625 | -- | -- | 50% 13.13K to 19.75K | |
| 09-Aug-23 8:42 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 07-Aug-23 | Option Exercise | 6,500 | -- | -- | 133% 4.88K to 11.38K | |
| 09-Aug-23 8:42 PM View: | Thorell Marella Chief Financial Officer | Evelo Biosciences, Inc. (EVLO) | 07-Aug-23 | Option Exercise | 6,500 | -- | -- | 142% 4.57K to 11.07K | |
| 13-Jul-23 5:15 PM View: | Flagship Ventures Fund Iv G... 10% Owner | Evelo Biosciences, Inc. (EVLO) | 11-Jul-23 | Private Purchase | 5,411,260 | $2.31 | $12,500,000.00 | 215% 2.52M to 7.93M | |
| 12-Jun-23 4:01 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 23-May-23 | Sale (Planned) | 22,571 | $0.14 | $3,200.57 | (8%) 285.13K to 262.56K | |
| 10-May-23 9:31 PM View: | Gill Simba President & CEO Director | Evelo Biosciences, Inc. (EVLO) | 08-May-23 | Sale (Planned) | 3,537 | $0.13 | $443.89 | (6%) 62.05K to 58.51K | |
| 10-May-23 9:31 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 08-May-23 | Sale (Planned) | 68,014 | $0.13 | $8,535.76 | (19%) 353.14K to 285.13K | |
| 10-May-23 9:32 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 08-May-23 | Sale (Planned) | 66,730 | $0.13 | $8,374.61 | (41%) 164.25K to 97.52K | |
| 10-May-23 9:31 PM View: | Thorell Marella Chief Financial Officer | Evelo Biosciences, Inc. (EVLO) | 08-May-23 | Sale (Planned) | 38,531 | $0.13 | $4,835.64 | (30%) 130.0K to 91.47K | |
| 09-May-23 4:09 PM View: | Gill Simba President & CEO Director | Evelo Biosciences, Inc. (EVLO) | 07-May-23 | Option Exercise | 23,437 | -- | -- | 61% 38.61K to 62.05K | |
| 09-May-23 4:08 PM View: | Bodmer Mark CSO, President of R&D | Evelo Biosciences, Inc. (EVLO) | 07-May-23 | Option Exercise | 132,500 | -- | -- | 60% 220.64K to 353.14K | |
| 09-May-23 4:08 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 07-May-23 | Option Exercise | 130,000 | -- | -- | 380% 34.25K to 164.25K | |
| 09-May-23 4:09 PM View: | Thorell Marella Chief Financial Officer | Evelo Biosciences, Inc. (EVLO) | 07-May-23 | Option Exercise | 130,000 | -- | -- | 100% 0 to 130.0K | |
| 02-Feb-23 4:10 PM View: | Plinio Mark D. Chief Commercial Officer | Evelo Biosciences, Inc. (EVLO) | 31-Jan-23 | Grant | 1,250 | $0.88 | $1,100.00 | 50% 2.5K to 3.75K | |
| 23-Jan-23 5:35 PM View: | Carriere Stephen J Principal Accounting Officer | Evelo Biosciences, Inc. (EVLO) | 23-Jan-23 | Option Sale | 151 | $1.06 | $160.12 | (43%) 0.35K to 0.2K | |
| 23-Jan-23 5:35 PM View: | Carriere Stephen J Principal Accounting Officer | Evelo Biosciences, Inc. (EVLO) | 19-Jan-23 | Option Exercise | 354 | -- | -- | 100% 0 to 0.35K | |
| 14-Oct-22 4:24 PM View: | Plinio Mark D. Chief Commercial Officer | Evelo Biosciences, Inc. (EVLO) | 29-Jul-22 | Grant | 1,250 | $1.79 | $2,237.50 | 100% 1.25K to 2.5K | |
| 30-Jun-22 4:52 PM View: | Epstein David R Director | Evelo Biosciences, Inc. (EVLO) | 30-Jun-22 | Option Exercise | 4,927 | -- | -- | 6% 89.0K to 93.93K | |
| 01-Jun-22 4:12 PM View: | Epstein David R Director | Evelo Biosciences, Inc. (EVLO) | 31-May-22 | Option Exercise | 4,925 | -- | -- | 6% 84.08K to 89.0K | |
| 01-Jun-22 7:00 PM View: | Flagship Ventures Fund Iv G... 10% Owner | Evelo Biosciences, Inc. (EVLO) | 27-May-22 | Private Purchase | 27,397,300 | $1.46 | $40,000,000.00 | 119% 23.03M to 50.43M | |
| 31-May-22 4:07 PM View: | Epstein David R Director | Evelo Biosciences, Inc. (EVLO) | 27-May-22 | Private Purchase | 17,123 | $1.46 | $24,999.60 | 26% 66.96K to 84.08K | |
| 31-May-22 4:11 PM View: | Darzi Lord Ara Director | Evelo Biosciences, Inc. (EVLO) | 27-May-22 | Private Purchase | 342,465 | $1.46 | $499,999.00 | 100% 0 to 342.46K | |
| 31-May-22 4:15 PM View: | McHale Duncan Chief Medical Officer | Evelo Biosciences, Inc. (EVLO) | 27-May-22 | Private Purchase | 34,246 | $1.46 | $49,999.20 | 100% 0 to 34.25K | |
| 02-May-22 4:03 PM View: | Epstein David R Director | Evelo Biosciences, Inc. (EVLO) | 02-May-22 | Option Exercise | 4,926 | -- | -- | 8% 62.03K to 66.96K | |
| 01-Apr-22 4:05 PM View: | Epstein David R Director | Evelo Biosciences, Inc. (EVLO) | 31-Mar-22 | Option Exercise | 4,926 | -- | -- | 9% 57.1K to 62.03K | |
| 01-Mar-22 4:07 PM View: | Epstein David R Director | Evelo Biosciences, Inc. (EVLO) | 28-Feb-22 | Option Exercise | 4,926 | -- | -- | 9% 52.18K to 57.1K | |
| 31-Jan-22 5:06 PM View: | Epstein David R Director | Evelo Biosciences, Inc. (EVLO) | 31-Jan-22 | Option Exercise | 4,925 | -- | -- | 10% 47.25K to 52.18K | |
| 01-Feb-22 5:31 PM View: | Plinio Mark D. Chief Commercial Officer | Evelo Biosciences, Inc. (EVLO) | 31-Jan-22 | Grant | 1,250 | $4.00 | $5,004.38 | 100% 0 to 1.25K | |
| 03-Jan-22 4:23 PM View: | Epstein David R Director | Evelo Biosciences, Inc. (EVLO) | 31-Dec-21 | Option Exercise | 4,926 | -- | -- | 12% 42.33K to 47.25K |
